Literature DB >> 10751594

Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.

B Czartoryska1, A Tylki-Szymańska, A Lugowska.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10751594     DOI： 10.1016/s0009-9120(99)00098-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN： 0009-9120            Impact factor:   3.281


× No keyword cloud information.
  12 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

2.  Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.

Authors:  Laura van Dussen; Timothy M Cox; Erik J Hendriks; Elizabeth Morris; Erik M Akkerman; Mario Maas; Johanna E M Groener; Johannes M F G Aerts; Patrick B Deegan; Carla E M Hollak
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Chitotriosidase as a marker of disease activity in sarcoidosis.

Authors:  Jürgen Brunner; Sabine Scholl-Bürgi; Martina Prelog; Lothar-Bernd Zimmerhackl
Journal:  Rheumatol Int       Date:  2007-01-25       Impact factor: 2.631

4.  Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients.

Authors:  Laura Deroma; Annalisa Sechi; Andrea Dardis; Daniela Macor; Giulia Liva; Giovanni Ciana; Bruno Bembi
Journal:  JIMD Rep       Date:  2012-07-01

5.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

6.  Chitotriosidase as a marker of disease activity in sarcoidosis.

Authors:  Jürgen Brunner; Sabine Scholl-Bürgi; Lothar-Bernd Zimmerhackl
Journal:  Rheumatol Int       Date:  2007-05-30       Impact factor: 2.631

7.  Chitotriosidase activity in juvenile idiopathic arthritis.

Authors:  Jürgen K H Brunner; Sabine Scholl-Bürgi; David Hössinger; Petra Wondrak; Martina Prelog; Lothar-Bernd Zimmerhackl
Journal:  Rheumatol Int       Date:  2008-03-07       Impact factor: 2.631

8.  Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.

Authors:  L van Dussen; E J Hendriks; J E M Groener; R G Boot; C E M Hollak; J M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2014-05-16       Impact factor: 4.982

9.  Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

Authors:  Jérôme Stirnemann; Christian Rose; Christine Serratrice; Florence Dalbies; Olivier Lidove; Agathe Masseau; Yves-Marie Pers; Camille Baron; Nadia Belmatoug
Journal:  Orphanet J Rare Dis       Date:  2015-05-13       Impact factor: 4.123

10.  Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.

Authors:  Maciej Machaczka; Cecilia Kämpe Björkvall; Joanna Wieremiejczyk; Martin Paucar Arce; Kristina Myhr-Eriksson; Monika Klimkowska; Hans Hägglund; Per Svenningsson
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-09-10       Impact factor: 4.291
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.